Literature DB >> 19431078

The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis.

Ferry Cornelissen1, Jan P van Hamburg, Erik Lubberts.   

Abstract

Rheumatoid arthritis (RA) was originally thought to be a T-helper (Th)1-, not a Th2-, associated disorder; however, it currently is unclear whether RA is a Th1- and/or Th17-mediated disease, and what the contributions of these T-cell subsets are in the pathogenesis of RA. Results from studies using different arthritis models have demonstrated that IL-17-producing T-cells are the dominant cell type in the development of arthritis. In addition, a critical role of the IL-23/IL-17 axis in the progression to chronic destructive arthritis has been demonstrated. Interestingly, Th1 and Th17 cells both may have unique pathogenic potential, and the recent insights into T-cell plasticity may change the understanding of the role of T-cell subsets in chronic autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19431078

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  19 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model.

Authors:  Jun Li; Hui-Chen Hsu; PingAr Yang; Qi Wu; Hao Li; Laura E Edgington; Matthew Bogyo; Robert P Kimberly; John D Mountz
Journal:  Arthritis Rheum       Date:  2011-10-13

3.  A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer.

Authors:  S Reppert; I Boross; M Koslowski; Ö Türeci; S Koch; H A Lehr; S Finotto
Journal:  Nat Commun       Date:  2011-12-20       Impact factor: 14.919

4.  Association of interleukin 23 receptor gene polymorphisms (rs10489629, rs7517847) with rheumatoid arthritis in European population: a meta-analysis.

Authors:  Yu Zhai; Ke Xu; Fen Huang; Hui Peng; Chen-Chen Feng; Kao-Kao Zhu; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-06-21       Impact factor: 2.316

5.  Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family.

Authors:  Weimin Kong; Jui-Hung Yen; Evros Vassiliou; Sabina Adhikary; Miguel G Toscano; Doina Ganea
Journal:  Lipids Health Dis       Date:  2010-02-01       Impact factor: 3.876

6.  Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition γδT cells.

Authors:  S Wang; X Xu; A Xie; J Li; P Ye; Z Liu; J Wu; L Rui; J Xia
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

7.  Lack of association between IL-23R gene polymorphisms and systemic lupus erythematosus in a Chinese population.

Authors:  Gui-Mei Chen; Chen-Chen Feng; Qian-Ling Ye; Juan Wang; Han Cen; Rui Li; Hui Peng; Mo Zhou; Rui-Xue Leng; Yin-Guang Fan; Jin-Hui Tao; Hai-Feng Pan; Dong-Qing Ye
Journal:  Inflamm Res       Date:  2013-06-11       Impact factor: 4.575

8.  Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects.

Authors:  Paul Eggleton; Edwin Bremer; Joanna M Tarr; Marco de Bruyn; Wijnand Helfrich; Alexandra Kendall; Richard C Haigh; Nick J Viner; Paul G Winyard
Journal:  Arthritis Res Ther       Date:  2011-12-15       Impact factor: 5.156

9.  The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system.

Authors:  Qin Wang; Xiaofeng Li; Jing Luo; Li Zhang; Lihui Ma; Zhiqin Lv; Lijin Xue
Journal:  BMC Musculoskelet Disord       Date:  2012-12-13       Impact factor: 2.362

10.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.